UAE-FED-NATIONAL-COUNCIL
9.1.2019 19:16:14 CET | Business Wire | Press release
His Excellency Antonio Tajani, President of the European Parliament, expressed his deep appreciation for the UAE’s global humanitarian and relief efforts, manifested through the work of the Emirates Red Crescent and described them as “really impressive”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190109005738/en/
His statement came during a brief speech delivered on Tuesday, January 8, 2019, during the opening of the three-day ‘Humanitarian Aid for Stability’ exhibition at the European Parliament in Brussels, Belgium. The event was organized by the Emirates Red Crescent in coordination with the Federal National Council (FNC), the parliamentary body of the UAE.
The opening of the exhibition drew the participation of Her Excellency Dr Amal Al Qubaisi, Speaker of FNC, His Excellency Fahad Abdelrahman Bin Sultan, Deputy Secretary General for International Aid at the Emirates Red Crescent, members of the European Parliament, and several ambassadors.
His Excellency Antonio Tajani called for joint action between the UAE and Europe to deal with illegal immigration, expand cooperation in this regard to the Middle East and Africa, and strengthen collaborative efforts to combat terrorism and enhance security. He added that ensuring stability and promoting development efforts in the world are common goals for the UAE and the EU.
His Excellency Antonio Tajani stressed that the refugee crisis is a global challenge, and therefore humanitarian aid must be a collective task that engages nations and peoples.
Furthermore, he thanked Antonio López-Istúriz White, Secretary General of the European People’s Party and member of the European Parliament, for his initiative in holding the exhibition that presented a novel opportunity to showcase the endeavors of valued partners of the EU to help alleviate the devastating effects of war. He added that war and natural disasters are the reasons for thousands of migrants trying to seek refuge in Europe.
His Excellency Antonio Tajani said: “The exhibition carries the positive message of hope. Yes, hope, because helping each other, providing a roof for people in need is providing hope, and hope is the fuel for a better tomorrow.”
In closing, he invited guests to view the exhibition that included a model of the Mrajeeb Al Fhood camp for Syrian refugees in Jordan and an interactive world map of areas in which the Emirates Red Crescent operates. He also highlighted the EU’s humanitarian commitment to helping refugees that places it at the forefront of humanitarian aid providers globally, and called for reinstating stability and security in the refugees’ home countries to overcome this global challenge.
Speaking on the sidelines of the launch of the exhibition, His Excellency Fahad Abdelrahman Bin Sultan said: “The humanitarian and development aid offered by the UAE to the world amounted to US$32.01 billion from 2013 to 2017 and benefited millions of people across the globe, including 10 million Yemenis.”
He added: “This exhibition is the first of its kind outside the UAE and was organized at the request of the European Parliament to explore the UAE’s international humanitarian, relief, and development role that is based on the country’s noble values and enhances the global humanitarian ecosystem.”
His Excellency Fahad Abdelrahman Bin Sultan stressed that the UAE humanitarian and development aid focuses on meeting the needs of refugees and displaced civilians in volatile areas, such as Syria, Yemen, Somalia, Palestine, Afghanistan, and Iraq. He pointed out that the UAE has gained international respect and trust, and placed first globally for the fifth consecutive year for its contribution of humanitarian and development aid relative to national GDP.
He noted that more than 100 countries have benefited from aid provided by the UAE, adding that the Emirates Red Crescent has 14 offices in countries such as Yemen, Somalia, Kazakhstan, Indonesia, Pakistan, Afghanistan, Bosnia, and Albania.
His Excellency Fahad Abdelrahman Bin Sultan outlined the distribution of the UAE humanitarian aid as follows: US$4.92 billion to Yemen from April 2015 to December 2018, around US$174.6 million to Libya from 2013 to 2017, around US$963.5 million to the Syrian people from 2012 to November 2018, around US$641.5 million to the people of Erbil (Iraq) from 2013 to 2017, around US$233.3 million to Somalia from 2013 to 2017, US$489 million to Palestinians from 2013 to 2018, and US$333.3 million to Afghanistan from 2013 to 2017.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20190109005738/en/
Contact:
Federal National Council, United Arab Emirates : Mohammed Al-Sawafi, +971506183874 m.alsawwafi@almajles.gov.ae Twitter: @FNC_UAE
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
